Loading…
Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials
In recent years, berberine has become widely used as an effective alternative to treat dyslipidaemias; much clinical evidence has emerged. It is important to systematically and critically evaluate the existing evidence. This study aims to evaluate the efficacy and safety of berberine in patients wit...
Saved in:
| Published in: | Phytomedicine (Stuttgart) 2018-11, Vol.50, p.25-34 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c362t-4979579efeaa4ccba35fb6c39e9c6c140a9ac5e69c8ef5cb47c00280fbce2553 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c362t-4979579efeaa4ccba35fb6c39e9c6c140a9ac5e69c8ef5cb47c00280fbce2553 |
| container_end_page | 34 |
| container_issue | |
| container_start_page | 25 |
| container_title | Phytomedicine (Stuttgart) |
| container_volume | 50 |
| creator | Ju, Jianqing Li, Jingen Lin, Qian Xu, Hao |
| description | In recent years, berberine has become widely used as an effective alternative to treat dyslipidaemias; much clinical evidence has emerged. It is important to systematically and critically evaluate the existing evidence.
This study aims to evaluate the efficacy and safety of berberine in patients with dyslipidaemias.
A systematic review and meta-analysis of randomized clinical trials.
Five electronic databases were searched up to Apr 15, 2018 to identify randomized controlled trials (RCTs) of berberine in treatment of dyslipidaemias. The outcomes were lipid profile parameters and adverse events. Study selection, data collection, risk of bias assessment, data analyses and interpretations were conducted according to the Cochrane handbook.
Sixteen trials with total of 2147 participants were judged to be eligible and were included in the meta-analysis. The included trials were assessed to be of high clinical heterogeneity. The methodological quality of the majority of the trials was generally low in terms of random sequence generation, allocation concealment, blinding and incomplete outcome data. Thus, selection bias, performance bias, detection bias, attrition bias and confounding bias might exist. Meta-analysis showed that berberine significantly reduced levels of total cholesterol (TC) (MD = -0.47 mmol/l 95% CI [-0.64, -0.31], p |
| doi_str_mv | 10.1016/j.phymed.2018.09.212 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2137472106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0944711318304951</els_id><sourcerecordid>2137472106</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-4979579efeaa4ccba35fb6c39e9c6c140a9ac5e69c8ef5cb47c00280fbce2553</originalsourceid><addsrcrecordid>eNp9kE9r3DAQxUVpaTZpv0EIOuZidyTLstVDISxpUwj0kkNvQh6PqBb_2UreJs6nr7abXAsDA6P35o1-jF0KKAUI_WlX7n-tI_WlBNGWYEop5Bu2EVq0BZj651u2AaNU0QhRnbHzlHYAQpkG3rOzCpTWptUb9nTrfUCHK3dTz5PztKx89ryjmCtMxP0ceb-mIexD72gMLn3mNzytaaHRLQF5pD-BHv_5R1pc4SY3rCmk45qYp_MYnqnnOIQpJw18icEN6QN753Ojjy_9gj18vX3Y3hX3P759397cF1hpuRT5YFM3hjw5pxA7V9W-01gZMqhRKHDGYU3aYEu-xk41CCBb8B2SrOvqgl2f1u7j_PtAabFjSEjD4CaaD8lKUTWqkQJ0lqqTFOOcUiRv9zGMLq5WgD0itzt7Qm6PyC2Y7JbZdvWScOiOb6-mV8ZZ8OUkoPzNjCrahIEmpD5EwsX2c_h_wl_-3Jdi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2137472106</pqid></control><display><type>article</type><title>Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials</title><source>ScienceDirect Journals</source><creator>Ju, Jianqing ; Li, Jingen ; Lin, Qian ; Xu, Hao</creator><creatorcontrib>Ju, Jianqing ; Li, Jingen ; Lin, Qian ; Xu, Hao</creatorcontrib><description>In recent years, berberine has become widely used as an effective alternative to treat dyslipidaemias; much clinical evidence has emerged. It is important to systematically and critically evaluate the existing evidence.
This study aims to evaluate the efficacy and safety of berberine in patients with dyslipidaemias.
A systematic review and meta-analysis of randomized clinical trials.
Five electronic databases were searched up to Apr 15, 2018 to identify randomized controlled trials (RCTs) of berberine in treatment of dyslipidaemias. The outcomes were lipid profile parameters and adverse events. Study selection, data collection, risk of bias assessment, data analyses and interpretations were conducted according to the Cochrane handbook.
Sixteen trials with total of 2147 participants were judged to be eligible and were included in the meta-analysis. The included trials were assessed to be of high clinical heterogeneity. The methodological quality of the majority of the trials was generally low in terms of random sequence generation, allocation concealment, blinding and incomplete outcome data. Thus, selection bias, performance bias, detection bias, attrition bias and confounding bias might exist. Meta-analysis showed that berberine significantly reduced levels of total cholesterol (TC) (MD = -0.47 mmol/l 95% CI [-0.64, -0.31], p < 0.00001), low-density lipoprotein cholesterol (LDL-C) (MD =-0.38 mmol/l 95% CI [-0.53, -0.22], p < 0.00001) and triglycerides (TG) (MD = -0.28 mmol/l 95% CI [-0.46, -0.10], p = 0.002). Berberine also increased the level of high-density lipoprotein cholesterol (HDL-C) when used alone (MD = 0.08 mmol/l 95% CI [0.03, 0.12], p = 0.001). No significant differences were found between groups in terms of incidence of adverse events (RR = 0.64 95% CI [0.31, 1.30], p = 0.22). No severe adverse effects were reported in either group.
Berberine improves lipid profiles in dyslipidaemias with satisfactory safety. Nevertheless, these findings should be interpreted with caution because of the high clinical heterogeneity and high risk of bias in the included trials. Rigorous clinical trials should be carried out to provide more reliable evidence.
[Display omitted]</description><identifier>ISSN: 0944-7113</identifier><identifier>EISSN: 1618-095X</identifier><identifier>DOI: 10.1016/j.phymed.2018.09.212</identifier><identifier>PMID: 30466986</identifier><language>eng</language><publisher>Germany: Elsevier GmbH</publisher><subject>Berberine ; Berberine - pharmacology ; CAD ; carotid atherosclerosis ; CAS ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; coronary artery disease ITT, intention-to-treat ; Dyslipidaemias ; Dyslipidemias - drug therapy ; HDL-C ; high-density lipoprotein cholesterol ; Humans ; IGT ; impaired glucose tolerance ; intention-to-treat ; ITT ; LDL-C ; Lipid profile ; lipid-lowering drugs ; Lipids - blood ; LLDs ; low-density lipoprotein cholesterol ; Meta-analysis ; Randomized controlled trial ; randomized controlled trials ; Randomized Controlled Trials as Topic ; RCTs ; Systematic review ; T2DM ; total cholesterol ; triglycerides ; Triglycerides - blood ; type 2 diabetes mellitus</subject><ispartof>Phytomedicine (Stuttgart), 2018-11, Vol.50, p.25-34</ispartof><rights>2018 Elsevier GmbH</rights><rights>Copyright © 2018 Elsevier GmbH. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-4979579efeaa4ccba35fb6c39e9c6c140a9ac5e69c8ef5cb47c00280fbce2553</citedby><cites>FETCH-LOGICAL-c362t-4979579efeaa4ccba35fb6c39e9c6c140a9ac5e69c8ef5cb47c00280fbce2553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30466986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ju, Jianqing</creatorcontrib><creatorcontrib>Li, Jingen</creatorcontrib><creatorcontrib>Lin, Qian</creatorcontrib><creatorcontrib>Xu, Hao</creatorcontrib><title>Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials</title><title>Phytomedicine (Stuttgart)</title><addtitle>Phytomedicine</addtitle><description>In recent years, berberine has become widely used as an effective alternative to treat dyslipidaemias; much clinical evidence has emerged. It is important to systematically and critically evaluate the existing evidence.
This study aims to evaluate the efficacy and safety of berberine in patients with dyslipidaemias.
A systematic review and meta-analysis of randomized clinical trials.
Five electronic databases were searched up to Apr 15, 2018 to identify randomized controlled trials (RCTs) of berberine in treatment of dyslipidaemias. The outcomes were lipid profile parameters and adverse events. Study selection, data collection, risk of bias assessment, data analyses and interpretations were conducted according to the Cochrane handbook.
Sixteen trials with total of 2147 participants were judged to be eligible and were included in the meta-analysis. The included trials were assessed to be of high clinical heterogeneity. The methodological quality of the majority of the trials was generally low in terms of random sequence generation, allocation concealment, blinding and incomplete outcome data. Thus, selection bias, performance bias, detection bias, attrition bias and confounding bias might exist. Meta-analysis showed that berberine significantly reduced levels of total cholesterol (TC) (MD = -0.47 mmol/l 95% CI [-0.64, -0.31], p < 0.00001), low-density lipoprotein cholesterol (LDL-C) (MD =-0.38 mmol/l 95% CI [-0.53, -0.22], p < 0.00001) and triglycerides (TG) (MD = -0.28 mmol/l 95% CI [-0.46, -0.10], p = 0.002). Berberine also increased the level of high-density lipoprotein cholesterol (HDL-C) when used alone (MD = 0.08 mmol/l 95% CI [0.03, 0.12], p = 0.001). No significant differences were found between groups in terms of incidence of adverse events (RR = 0.64 95% CI [0.31, 1.30], p = 0.22). No severe adverse effects were reported in either group.
Berberine improves lipid profiles in dyslipidaemias with satisfactory safety. Nevertheless, these findings should be interpreted with caution because of the high clinical heterogeneity and high risk of bias in the included trials. Rigorous clinical trials should be carried out to provide more reliable evidence.
[Display omitted]</description><subject>Berberine</subject><subject>Berberine - pharmacology</subject><subject>CAD</subject><subject>carotid atherosclerosis</subject><subject>CAS</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>coronary artery disease ITT, intention-to-treat</subject><subject>Dyslipidaemias</subject><subject>Dyslipidemias - drug therapy</subject><subject>HDL-C</subject><subject>high-density lipoprotein cholesterol</subject><subject>Humans</subject><subject>IGT</subject><subject>impaired glucose tolerance</subject><subject>intention-to-treat</subject><subject>ITT</subject><subject>LDL-C</subject><subject>Lipid profile</subject><subject>lipid-lowering drugs</subject><subject>Lipids - blood</subject><subject>LLDs</subject><subject>low-density lipoprotein cholesterol</subject><subject>Meta-analysis</subject><subject>Randomized controlled trial</subject><subject>randomized controlled trials</subject><subject>Randomized Controlled Trials as Topic</subject><subject>RCTs</subject><subject>Systematic review</subject><subject>T2DM</subject><subject>total cholesterol</subject><subject>triglycerides</subject><subject>Triglycerides - blood</subject><subject>type 2 diabetes mellitus</subject><issn>0944-7113</issn><issn>1618-095X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kE9r3DAQxUVpaTZpv0EIOuZidyTLstVDISxpUwj0kkNvQh6PqBb_2UreJs6nr7abXAsDA6P35o1-jF0KKAUI_WlX7n-tI_WlBNGWYEop5Bu2EVq0BZj651u2AaNU0QhRnbHzlHYAQpkG3rOzCpTWptUb9nTrfUCHK3dTz5PztKx89ryjmCtMxP0ceb-mIexD72gMLn3mNzytaaHRLQF5pD-BHv_5R1pc4SY3rCmk45qYp_MYnqnnOIQpJw18icEN6QN753Ojjy_9gj18vX3Y3hX3P759397cF1hpuRT5YFM3hjw5pxA7V9W-01gZMqhRKHDGYU3aYEu-xk41CCBb8B2SrOvqgl2f1u7j_PtAabFjSEjD4CaaD8lKUTWqkQJ0lqqTFOOcUiRv9zGMLq5WgD0itzt7Qm6PyC2Y7JbZdvWScOiOb6-mV8ZZ8OUkoPzNjCrahIEmpD5EwsX2c_h_wl_-3Jdi</recordid><startdate>20181115</startdate><enddate>20181115</enddate><creator>Ju, Jianqing</creator><creator>Li, Jingen</creator><creator>Lin, Qian</creator><creator>Xu, Hao</creator><general>Elsevier GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181115</creationdate><title>Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials</title><author>Ju, Jianqing ; Li, Jingen ; Lin, Qian ; Xu, Hao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-4979579efeaa4ccba35fb6c39e9c6c140a9ac5e69c8ef5cb47c00280fbce2553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Berberine</topic><topic>Berberine - pharmacology</topic><topic>CAD</topic><topic>carotid atherosclerosis</topic><topic>CAS</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>coronary artery disease ITT, intention-to-treat</topic><topic>Dyslipidaemias</topic><topic>Dyslipidemias - drug therapy</topic><topic>HDL-C</topic><topic>high-density lipoprotein cholesterol</topic><topic>Humans</topic><topic>IGT</topic><topic>impaired glucose tolerance</topic><topic>intention-to-treat</topic><topic>ITT</topic><topic>LDL-C</topic><topic>Lipid profile</topic><topic>lipid-lowering drugs</topic><topic>Lipids - blood</topic><topic>LLDs</topic><topic>low-density lipoprotein cholesterol</topic><topic>Meta-analysis</topic><topic>Randomized controlled trial</topic><topic>randomized controlled trials</topic><topic>Randomized Controlled Trials as Topic</topic><topic>RCTs</topic><topic>Systematic review</topic><topic>T2DM</topic><topic>total cholesterol</topic><topic>triglycerides</topic><topic>Triglycerides - blood</topic><topic>type 2 diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ju, Jianqing</creatorcontrib><creatorcontrib>Li, Jingen</creatorcontrib><creatorcontrib>Lin, Qian</creatorcontrib><creatorcontrib>Xu, Hao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Phytomedicine (Stuttgart)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ju, Jianqing</au><au>Li, Jingen</au><au>Lin, Qian</au><au>Xu, Hao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials</atitle><jtitle>Phytomedicine (Stuttgart)</jtitle><addtitle>Phytomedicine</addtitle><date>2018-11-15</date><risdate>2018</risdate><volume>50</volume><spage>25</spage><epage>34</epage><pages>25-34</pages><issn>0944-7113</issn><eissn>1618-095X</eissn><abstract>In recent years, berberine has become widely used as an effective alternative to treat dyslipidaemias; much clinical evidence has emerged. It is important to systematically and critically evaluate the existing evidence.
This study aims to evaluate the efficacy and safety of berberine in patients with dyslipidaemias.
A systematic review and meta-analysis of randomized clinical trials.
Five electronic databases were searched up to Apr 15, 2018 to identify randomized controlled trials (RCTs) of berberine in treatment of dyslipidaemias. The outcomes were lipid profile parameters and adverse events. Study selection, data collection, risk of bias assessment, data analyses and interpretations were conducted according to the Cochrane handbook.
Sixteen trials with total of 2147 participants were judged to be eligible and were included in the meta-analysis. The included trials were assessed to be of high clinical heterogeneity. The methodological quality of the majority of the trials was generally low in terms of random sequence generation, allocation concealment, blinding and incomplete outcome data. Thus, selection bias, performance bias, detection bias, attrition bias and confounding bias might exist. Meta-analysis showed that berberine significantly reduced levels of total cholesterol (TC) (MD = -0.47 mmol/l 95% CI [-0.64, -0.31], p < 0.00001), low-density lipoprotein cholesterol (LDL-C) (MD =-0.38 mmol/l 95% CI [-0.53, -0.22], p < 0.00001) and triglycerides (TG) (MD = -0.28 mmol/l 95% CI [-0.46, -0.10], p = 0.002). Berberine also increased the level of high-density lipoprotein cholesterol (HDL-C) when used alone (MD = 0.08 mmol/l 95% CI [0.03, 0.12], p = 0.001). No significant differences were found between groups in terms of incidence of adverse events (RR = 0.64 95% CI [0.31, 1.30], p = 0.22). No severe adverse effects were reported in either group.
Berberine improves lipid profiles in dyslipidaemias with satisfactory safety. Nevertheless, these findings should be interpreted with caution because of the high clinical heterogeneity and high risk of bias in the included trials. Rigorous clinical trials should be carried out to provide more reliable evidence.
[Display omitted]</abstract><cop>Germany</cop><pub>Elsevier GmbH</pub><pmid>30466986</pmid><doi>10.1016/j.phymed.2018.09.212</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0944-7113 |
| ispartof | Phytomedicine (Stuttgart), 2018-11, Vol.50, p.25-34 |
| issn | 0944-7113 1618-095X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2137472106 |
| source | ScienceDirect Journals |
| subjects | Berberine Berberine - pharmacology CAD carotid atherosclerosis CAS Cholesterol, HDL - blood Cholesterol, LDL - blood coronary artery disease ITT, intention-to-treat Dyslipidaemias Dyslipidemias - drug therapy HDL-C high-density lipoprotein cholesterol Humans IGT impaired glucose tolerance intention-to-treat ITT LDL-C Lipid profile lipid-lowering drugs Lipids - blood LLDs low-density lipoprotein cholesterol Meta-analysis Randomized controlled trial randomized controlled trials Randomized Controlled Trials as Topic RCTs Systematic review T2DM total cholesterol triglycerides Triglycerides - blood type 2 diabetes mellitus |
| title | Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A53%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20berberine%20for%20dyslipidaemias:%20A%20systematic%20review%20and%20meta-analysis%20of%20randomized%20clinical%20trials&rft.jtitle=Phytomedicine%20(Stuttgart)&rft.au=Ju,%20Jianqing&rft.date=2018-11-15&rft.volume=50&rft.spage=25&rft.epage=34&rft.pages=25-34&rft.issn=0944-7113&rft.eissn=1618-095X&rft_id=info:doi/10.1016/j.phymed.2018.09.212&rft_dat=%3Cproquest_cross%3E2137472106%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-4979579efeaa4ccba35fb6c39e9c6c140a9ac5e69c8ef5cb47c00280fbce2553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2137472106&rft_id=info:pmid/30466986&rfr_iscdi=true |